3.39↑0.00 (0.00%)
04:01 PM,21st Aug 2023BSE : 524689
NSE : PDPL
Sector : Health care
ISIN Code : INE904D01019
Last Updated: Aug 21 2023 | 04:01 PM IST
Market Cap (₹ Cr) | 0 |
Turnover (₹ Cr) | 0.00 |
Volume (Shares) | |
Face Value | 10 |
52-WK High | 4.80 |
52-WK High Date | 31 Oct 2022 |
52-WK Low | 2.70 |
52-WK Low Date | 21 Aug 2023 |
All Time High | 400.00 |
All Time High Date | 11 Nov 2010 |
All Time Low | 2.20 |
All Time Low Date | 14 Oct 2019 |
Parenteral Drugs (India) Ltd is an India-based pharmaceutical company. The company develops manufactures and markets a range of pharmaceutical products in India. Their products include solid and liquid orals such as antibiotics and anti-bacterial anti-ulcerant analgesics/anti-inflammatory multivitamins and minerals anxiolyic antiprotozoal anticold anthelmintic anti-histaminic muscle relaxant cardiac antidiabetic cough syrup appetite enhancer and injections. The company produces various therapeutic segments of In-Vitro (I V) Fluids such as electrolytes antibacterial energy replenisher irrigation solution osmotic diuretic dialysis solution. They also produce 400-milligram Ciprofloxacin infusion in 200 milliliter with 5% dextose. Apart from the single dose dispensers the company has also launched multi-dose eye/ ear drops in plastic containers. The dispensers are made using the form-fill-seal technology.Parenteral Drugs (India) Ltd was incorporated in the year 1983 as a private limited company. In the year 1989 the company established their first unit to manufacture I V Fluids in Polypropylene containers with a capacity of 18 lakh bottles per annum. In March 1994 the company was converted into a public limited company. In September 1994 the company came out with a public issue at a premium of Rs 80 aggregating Rs 7.03 crore to part-finance their Rs 8.97crore expansion. During the year 1994-95 the company set up a joint venture unit in Ukraine for manufacture of a wide range of pharmaceuticals. In addition they set up a unit for the manufacture of I V Fluids at Jalandhar in Punjab. During the year 1997-98 the company purchased 100% equity of the Parenteral Drugs International Ltd and made it a wholly owned subsidiary of the company. They also purchased 50% equity in Parental Drugs (Punjab) Ltd. During the year 1999-2000 the company was awarded ISO 9002 Certification as a symbol of quality products.During the year 2003-04 the company installed Injections with the production capacity of 516 lakh numbers. During the year 2005-06 the company increased the production capacity of I V Fluid Transfusion by 45000000 Nos to 120000000 Nos. In addition they set up a plant for manufacturing pharmaceutical products at Baddi in Himachal Pradesh. During the year 2006-07 the company increased the production capacity of Tablets/ Capsules by 1125000000 Nos Ampoules by 90000000 Nos and Injections 56400000 Nos. During the year 2007-08 they increased the production capacity of Large Volume by 30000000 Nos and Ampoules by 95000000 Nos.The Scheme of Amalgamation was sanctioned by the Hon'ble High Court of Judicature at Bombay vide its Order dated 12th October 2009. Under the scheme of amalgamation M/s. PFL Holdings Private Limited and M/s. Goa Holdings (India) Private Limited amalgamated with the Company and consequently M/s.Punjab Formulations Limited and M/s.Goa Formulations Limited became wholly-owned subsidiaries of the Company with effect from 1st November 2008.The Company incorporated a wholly-owned subsidiary in Kazakhstan in the name of Parenteral Drugs Kazakhstan to undertake the business of manufacturing of pharmaceutical products during 2008. In 2009 the Company launched products comprised of Falcistar and Merogol for Injections and tablets/ capsules like Azimist and Megastar. It launched the products under the oncology (anti-cancer) segment comprising of Fludapar Trexopar Mindro and Ifoparwith Mesna.During 2009-10 Company converted 1200000 warrants into equity shares of Rs. 10/-each which were issued by way of preferential allotment on 24th August 2009 which were allotted to M/s.Mahaganpati Investments Private Limited a Company under Promoter Category. During FY 2010-11 10 new products such as GRASIPAR PFS LEUCOPAR-50 INJECTION PACOFF EXPECTORANT PIDIMOL IV 5 FU-PAR INJECTION BOTEPAR INJECTION ERLOPAR TABLETS TEGNID INJECTION CEFACE CV TABLETS ERLOPAR TABLETS ANTOXY-2 SYRUP and TAMOLGAN IV were introduced in the market.In 2014 Punjab Formulations Limited a wholly owned subsidiary ceased to be in existence as the said Company was amalgamated with Infutec Healthcare Limited (Formerly: Goa Formulations Limited) a wholly owned subsidiary of the Company w.e.f. 12 September 2014 vide Order of the Honorable High Court of Bombay Judicature.During year 2015-16 Company disinvested equity investment in two subsidiary companies namely Parentech Healthcare Limited and Parenteral Surgicals Limited. During 2016-2017 the Company disinvested from the equity shares held in its 2 subsidiary companies namely Abhay Drugs Limited and Anjaney Pharmaceuticals Limited. During the year 2018-19 Infutec Healthcare Limited an erstwhile wholly owned subsidiary ceased to be a subsidiary of company w.e.f 10 July 2018.
PARAMETER | VALUES |
---|---|
Market Cap (₹ Cr) | 10 |
EPS - TTM (₹) [S] | 0.00 |
P/E Ratio (X) [S] | -0.01 |
Face Value (₹) | 10 |
Latest Dividend (%) | 20.00 |
Latest Dividend Date | 13 Sep 2010 |
Dividend Yield (%) | - |
Book Value Share (₹) [S] | -300.60 |
P/B Ratio (₹) [S] | -0.01 |
[*C] Consolidated [*S] Standalone |
Scheme Name ↑↓ | Amount Invested ( ₹ Cr ) ↑↓ | No Of Shares ↑↓ | Net Asset (%) ↑↓ |
---|---|---|---|
DSP Midcap Fund (G) | 2.85 | 146927 | 0.26 |
Date↑↓ | Broker↑↓ | Action↑↓ | Prices(Rs)↑↓ | Report |
---|---|---|---|---|
Data Not Found |
Today's Low/High | 3.08 3.39 |
Week Low/High | 0.00 3.39 |
Month Low/High | 0.00 3.39 |
Year Low/High | 3.08 5.00 |
All time Low/High | 0.38 400.00 |
Period | BSE | NSE | SENSEX | NIFTY |
---|---|---|---|---|
1 Week | % | % | -0.27 | -0.18% |
1 Month | % | % | 1.16 | 1.53% |
3 Month | % | % | 2.99 | 3.51% |
6 Month | % | % | 14.26 | 15.85% |
1 Year | % | -9.38% | 16.70 | 16.77% |
3 Year | % | % | 73.35 | 74.99% |
Date | Client Name | Exchange | Transaction | Quantity | Price |
---|---|---|---|---|---|
28-02-2014 | CHIRAAYUSH STOCK CONSULTANTS PRIVATE LIMITED | BSE | SELL | 159830 | 27.50 |
28-02-2014 | SYSTEMATIX FINCORP INDIA LIMITED | BSE | BUY | 159830 | 27.50 |
22-10-2010 | DHANANJAYA MONEY MANAGEMENT SERVICES PVT LTD | BSE | BUY | 117040 | 328.09 |
15-10-2010 | DHANANJAYA MONEY MANAGEMENT SERVICES PVT LTD | BSE | BUY | 150139 | 313.01 |
15-10-2010 | IL & FS FINANCIAL SERVICES LIMITED | BSE | BUY | 155000 | 290.00 |
15-10-2010 | INDIA DISCOVERY FUND LIMITED | BSE | BUY | 790000 | 290.00 |
15-10-2010 | JMP SECURITIES PVT LTD | BSE | SELL | 204019 | 307.66 |
15-10-2010 | JMP SECURITIES PVT LTD | BSE | BUY | 218569 | 293.45 |
15-10-2010 | KADAYAM RAMNATHAN BHARAT | BSE | SELL | 200000 | 290.56 |
15-10-2010 | MADHUKAR CHIMANLAL SHETH | BSE | BUY | 1389303 | 306.77 |
Load More |
Name | Price(In Rs) | Chg(%) | Mkt Cap(Rs Cr) | Sales(Rs Cr) | Profit(Rs Cr) | EPS(Rs) | P/E(x) |
---|
Category | Share(%) |
---|---|
Promoter | 73.29 |
Financial Institutions Banks | 0.00 |
Foreign Institutional Investors | 0.00 |
Insurance Companies | 0.00 |
Mutual Funds Uti | 0.01 |
Other Institutional Investors | 0.00 |
Indian Public | 21.74 |
Others Non Institutional Investors | 4.97 |
Custodians | 0.00 |
Announcement Date | Purpose | From | To | Remarks |
---|---|---|---|---|
Data Not Found |
Search for Price History
Date | Open | High | Low | Close | Shares | Trades |
---|---|---|---|---|---|---|
Data Not Found |
Load more
Chairman : Manoharlal Gupta
Whole-time Director : Govind Das Garg
Independent Director : Dharam Pal Khanna
Independent Director : Dilip Kumar Sinha
Non Executive Director : Anil Mittal
Independent Director : Manish Verma
Managing Director & CFO : Vinod Kumar Gupta
Independent Director : Deepali Garhewal
Independent Director : Chhaya Gupta
Registered Office: 340 Laxmi Plaza Laxmi Indl Est, New Link Road Andheri (West),Mumbai,Maharashtra-400053 Ph: 91-022-61725900-1
Email:pdpl@pdlindia.com